Cost-Benefit Analysis of Hydrogen Breath Test-Directed Rifaximin for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Clin Gastroenterol Hepatol. 2023 Sep;21(10):2695-2696.e1. doi: 10.1016/j.cgh.2022.09.010. Epub 2022 Sep 22.

Authors

Alicia Muratore¹, Eric D Shah², Walter W Chan³

Affiliations

¹ Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Business School, Boston, Massachusetts.
² Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Health, Lebanon, New Hampshire.
³ Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: wwchan@bwh.harvard.edu.

PMID: 36152896
DOI: 10.1016/j.cgh.2022.09.010

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Breath Tests
Cost-Benefit Analysis
Diarrhea / drug therapy
Humans
Hydrogen
Irritable Bowel Syndrome* / complications
Irritable Bowel Syndrome* / drug therapy
Rifamycins*
Rifaximin

Substances

Rifaximin
Hydrogen
Rifamycins